• Publications

    1. In cell Mutational Interference Mapping Experiment (in cell MIME) identifies regulatory RNA controlling HIV-1 replication, Redmond P Smyth*$, Maureen Smith$, Anne-Caroline Jousset, Laurence Despons, Geraldine Laumond, Thomas Decoville, Pierre Cattenoz, Christiane Moog, Fabrice Jossinet, Marylene Mougel, Jean-Christophe Paillart, Max von Kleist*, Roland Marquet*, submitted, 2017
    2. Reconstruction of the genetic history and the current spread of HIV-1 subtype A in Germany. Kirsten Hanke, Nuno Rodriguez Faria, Denise Kühnert, Kaveh Pouran Yousef, Andrea Hauser, Karolin Meixenberger, Alexandra Hofmann, Viviane Bremer, Barbara Bartmeyer, Oliver Pybus, Claudia Kücherer, Max von Kleist, and Norbert Bannert, submitted, 2017
    3. Local c-di-GMP signaling in the control of synthesis of the E. coli biofilm exopolysaccharide cellulose. A.M. Richter, KP. Yousef, M. von Kleist, R. Hengge, submitted, 2017
    4. Statistical analysis of the first passage path ensemble of jump processes. M.  von Kleist, Ch. Schütte, W. Zhang, submitted (arXiv), 2017
    5. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors. K. Meixenberger, K. P. Yousef, S. Somogyi, Sybille, S. Fiedler, B. Bartmeyer, O.  Hamouda, N. Bannert, M.  von Kleist, C. Kücherer, submitted 2017
    6. Optimal control of markov jump processes: Asymptotic analysis, algorithms and application to modelling of chemical reaction systems. W. Zhang, C. Hartmann and M. von Kleist, submitted (arXiv), 2016
    7. In silico cytotoxicity assessment on cultured rat intestinal cells deduced from cellular impedance measurements. P. Gupta, A. Gramatke, R. Einspanier, C. Schütte, M.von Kleist*, J. Sharbati*Toxicology in vitro, 41, 179, 2017 (online)*equally contributed
    8. Coupling cellular phenotype and mechanics to understand extracellular matrix formation and homeostasis in osteoarthritis. V. Sunkara, M. von Kleist,
      IFAC-PapersOnLine 49(26), 38, 2016 (online,preprint)
    9. Preconditioned Metropolis sampling as a strategy to improve efficiency in Posterior exploration. Stefan Engblom, Vikram Sunkara, IFAC-PapersOnLine 49(26), 89, 2016 (online,preprint)
    10. MIMEAnTo-Profiling functional RNA in Mutational Interference Mapping Experiments. M. Smith, R. P. Smyth, R. Marquet and M. von KleistBioinformatics, 32, 3369, 2016 (open access)
    11. Multi-scale Systems-Pharmacology pipeline to assess the prophylactic efficacy of NRTIs against HIV-1. S. Duwal, V. Sunkara and M. von Kleist, CPT: Pharmacometrics & Systems Pharmacology, 5, 377, 2016 (open access)
    12. Inferring HIV-1 transmission dynamics in Germany from recently transmitted viruses. K. P. Yousef, K. Meixenberger, M. R. Smith, S. Somogyi, S. Gromöller, D. Schmidt, B. Gunsenheimer-Bartmeyer. O. Hamouda, C. Kücherer and M. von Kleist, Journal of Acquired Immune Deficiency Syndromes, 73, 356, 2016 (online)
    13. Top-down and bottom-up modelling in system pharmacology to understand clinical efficacy : An example with NRTIs of HIV-1. S. Duwal, M. von Kleist, Eur J Parm Sci, 94, 72, 2016 (online)
    14. Mutational Interference Mapping Experiment (MIME) for studying the relationship between RNA structure and function. R.P. Smyth*, L. Despons, G. Huili, S. Bernacchi, M. Hijnen, J. Mak, F. Jossinet, L. Weixi, J-C. Paillart, M. von Kleist*, R. Marquet*, Nature Methods+, 12, 866 , 2015 (online) *shared corresponding authorship. +see also cover of the september issue
    15. Logical-continuous modelling of post-translationally regulated bistability of curli fiber expression in Echerichia coli. K. P. Yousef, A. Streck, C. Schütte, H. Siebert, R. Hengge and M. von Kleist, BMC Systems Biology, 9, 39, 2015 (open access)
    16. Optimal treatment strategies in the context of ‘treatment for prevention’ against HIV-1 in resource-poor settings. S. Duwal, S. Winkelmann, C. Schütte and M. von Kleist, PLoS Comput. Biol., 11, e1004200, 2015 (open access)
    17. Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany. K. Meixenberger, K. P. Yousef, S. Somogyi, S. Fiedler, B. Bartmeyer, M. von Kleist, C. Kücherer. Journal of the International AIDS Society 11/2014; 17(4(Suppl 3)):19746.
    18. Assessment of ambiguous base calls in HIV-1 pol population sequences as a biomarker to indentify recent infections in HIV-1 incidence studies. K. Meixenberger, A. Hauser, K. Jansen, K. P. Yousef, S. Fiedler, M. von Kleist, S. Norley, S.Somogyi, O. Hamouda, N. Bannert, B. Bartmeyer, C. Kücherer. Journal of Clinical Microbiology52, 2977, 2014 (online)
    19. Awareness and Utilization of Standards and Pathways for the Reporting of Adverse Events Following Immunization among Pediatricians in Russia and Germany. S. Muehlhans, M. von Kleist, T. Gretchukha, T. Martin, U. Fegeler, W. Maurer, L. Namazova-Baranova, G. Gaedicke, A. Baranov, B. Rath. Pediatric Drugs16, 321, 2014 (online)
    20. “Time-to-Amphotericin B” in Cryptococcal Meningitis in a European Low-Prevalence Setting: Analysis of Diagnostic Delays. J. Katchanov, M. von Kleist, K. Arasteh, H. Stocker QJM: An International Journal of Medicine, 107, 799, 2014 (online)
    21. Quantitative influenza follow-up testing (QIFT) – a novel biomarker for the monitoring of disease activity at the point-of-care. X. Chen, K. P. Yousef, S. Duwe, K. Karsch, S. Grover, S. Wählisch, P. Obermeier, F. Tief, S. Muehlhans, L. Seeber, M. von Kleist, B. Schweiger, B. Rath. Plos One 9, e92500, 2014 (open access)
    22. Markov Control Processes with Rare State Observation: Theory and Application to Treatment Scheduling in HIV-1 S. Winkelmann, C. Schütte and M. von KleistCommunications in Mathematical Sciences 12, 859, 2014 (online)
    23. “Markov Control with Rare State Observation”: Sensitivity Analysis with Respect to Optimal Treatment Strategies against HIV-1. S. Winkelmann, C. Schütte and M. von Kleist. International Journal of Biomathematics and Biostatistics 2, 1, 2013 (pdf of preprint)
    24. Towards a personalized approach to managing of influenza infections in infants and children – food for thought and a note on oseltamivir B. Rath, F. Tief, K. Karsch, S. Muehlhans, P. Obermeier, E. Adamou, X. Chen, L. Seeber, C. Peiser, C. Hoppe, M. von Kleist, T. Conrad, B. Schweiger. Infectious Disorders – Drug Targets 13 , 25, 2013 (online)
    25. In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis
      B. Rath, K. P. Yousef, D. K. Katzenstein, R. W. Shafer, Ch. Schütte, M. von Kleist and T. C. Merigan. PLoS One 8 , e61102, 2013 (open access)
    26. Antiviral Resistance and Predictors of Virologic Failure in the first Cohort of HIV-infected Children Gaining Access to Structured Antiretroviral Therapy in Lima, Peru: A Cross-Sectional Analysis B. Rath, M. von Kleist, M. E. Castillo, L. Kolevic, P. Caballero, G. Soto-Castellares, A. M. Amedee, J. E. Robinson, D. K. Katzenstein, R. B. Van Dyke and R. Oberhelman BMC Infect Dis 13, 1, 2013 (open access)
    27. Pharmacokinetics and Pharmacodynamics of the Reverse Transcriptase Inhibitor Tenefovir and Prophylactic Efficacy against HIV-1 Infection. S. Duwal, C. Schütte and M. von Kleist. PLoS One 8, e40382, 2012 (open access)
    28. Virus Load Kinetics and Resistance Development during Oseltamivir Treatment in Infants and Children Infected with Influenza A (H1N1) 2009 and Influenza B Viruses B. Rath, M. von Kleist, F. Tief, K. Karsch, E. Türk, S. Mühlhans, F. Louis, H. Skopnik, B. Schweiger and S. Duwe. Pediatr Infect Dis J. 31, 9, 2012(online)
    29. HIV-1 polymerase inhibition by nucleoside analogs: Cellular- and kinetic parameters of efficacy, susceptibility and resistance selection M. von Kleist, P. Metzner, R. Marquet and C. Schütte. PLoS Comput. Biol.8, e1002359, 2012 (open access)
    30. Quantifying the impact of nevirapine-based prophylaxis strategies to prevent mother-to-child transmission of HIV-1: A combined pharmacokinetic, pharmaco- and viral dynamic analysis to predict clinical outcomes. M. Frank*, M. von Kleist*, A. Kunz, G. Harms, C. Schütte and C. Kloft. Antimicrob. Agents Chemother 55, 5529, 2011 (open access)* equally contributed
    31. Reduction technique for pharmacological models to support planning, execution and analysis of clinical studies (patent).
      M. von Kleist (67%) and Christof Schutte (33%) . German patent office. Pat.Nr.: 10 2010 060 311, 2010 (link)
    32. HIV quasi-species dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs. M. von Kleist, S. Menz, H. Stocker, K. Arasteh, C. Schütte and W. Huisinga. PLoS ONE 6, e18204, 2011 (open access)
    33. A Drug-Class specific impact of antivirals on the reproductive capacity of HIV. M. von Kleist, Stephan Menz and W. Huisinga. PLoS Comput. Biol. 6, e1000720, 2010 ( open access )
    34. Pharmacokinetic-Pharmacodynamic relationship of NRTIs and its connection to viral escape: An example based on Zidovudine M. von Kleist and W. Huisinga Eur J Pharm Sci 36, 532, 2009 (online)
    35. Combining Systems Biology with physiologically-based pharmacokinetics to support the understanding of drug effects. M. von Kleist, C. Kloft and W. Huisinga. Proceedings of Foundations of Systems Biology in Engeneering FOSBE, 231, 2007 (pdf of preprint)
    36. Physiologically based pharmacokinetic modelling: A sub-compartmentalized model of tissue distribution
      M. von Kleist and W. Huisinga. J. Pharmakokinet. Pharmacodyn. 34, 789, 2007 (online)
    37. Software Supported Modelling in Pharmacokinetics R. Telgmann, M. von Kleist, and W. Huisinga LNCS 4216, 216, 2006 (online)
    38. Update on Antiviral DNA Vaccine Research (2000-2003) D. Franke, J. Pavlovic, T. S. Utesch, M. von Kleist, J. Schultz, G. Dollenmaier and K. Moelling. in Novel Vaccination Strategies Stefan H. E. Kaufmann (ed.), Wiley 2004 (online)